Table 5.

Anticoagulant use from index date to first post-index VTE event

	Overall (N=2299)	ICI (N=605)	Chemo (N=1092)	ICI+chemo (N=602)
Among patients with VTE events during follow-up, n (%)	404 (17.6)	82 (13.6)	206 (18.9)	116 (19.3)
Patients with anticoagulant use, n (%)	121 (30.0)	21 (25.6)	70 (34.0)	30 (25.9)
Treatment duration of medications from index  date to first post-index VTE event, mean days	48.3	69.9	51.4	27.6
Low-molecular-weight heparins, n (%)	66 (16.3)	10 (12.2)	43 (20.9)	13 (11.2)
Warfarin, n (%)	12 (3.0)	≤10 (3.7)	≤10 (3.9)	≤10 (0.9)
Direct-acting oral anticoagulants, n (%)	59 (14.6)	10 (12.2)	33 (16.0)	16 (13.8)
Fondaparinux, n (%)	≤10 (0.7)	0	≤10 (1.5)	0

ICI, immune checkpoint inhibitor; VTE, venous thromboembolism.